Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $101.35, but opened at $78.62. Sarepta Therapeutics shares last traded at $79.25, with a volume of 2,825,667 shares changing hands.
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft decreased their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a report on Wednesday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a report on Tuesday. HC Wainwright reissued a "sell" rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday. Scotiabank reduced their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research report on Thursday. Finally, Piper Sandler cut their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 27th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Sarepta Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $167.41.
Check Out Our Latest Report on Sarepta Therapeutics
Sarepta Therapeutics Price Performance
The company has a market cap of $7.19 billion, a price-to-earnings ratio of 59.28 and a beta of 0.79. The company has a 50-day simple moving average of $107.19 and a 200-day simple moving average of $118.00. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.
Insider Buying and Selling
In related news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 7.70% of the stock is owned by insiders.
Institutional Trading of Sarepta Therapeutics
A number of institutional investors have recently bought and sold shares of the company. Manchester Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after buying an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 156 shares during the last quarter. Sunbelt Securities Inc. lifted its holdings in shares of Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 232 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $36,000. Finally, Steward Partners Investment Advisory LLC increased its stake in shares of Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 194 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
(
Get Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Recommended Stories
Before you consider Sarepta Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.
While Sarepta Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
